ADC Therapeutics Reports Q1 2026 Earnings Call Details
ADC Therapeutics reported a 15% year-over-year revenue growth attributed primarily to customer ordering variability rather than increased market demand. The company is focusing on expanding ZYNLONTA into earlier lines of therapy and indolent lymphomas, with peak U.S. annual revenues projected between $600 million and $1 billion.
Tickers: $ADCT
Topics: Biotech Clinical Trials Financial Performance Pharmaceuticals